Paid Clinical Trials Indiana

Discover 1,108 paid clinical trials in Indiana. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,108

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionA Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Recruiting

PHASE1

PHASE2

Sponsor:

Amgen

Location:

Indianapolis IN, Detroit MI, Nashville TN, Torontoshow 9 more

Code:

NCT05325866

Conditions

Solid Tumors

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Bemarituzumab

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic MalignanciesTolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Recruiting

PHASE1

Sponsor:

Vanda Pharmaceuticals

Location:

Lafayette IN, Fairway KS, Washington DC, Hackensack NJshow 1 more

Code:

NCT03838926

Conditions

Relapsed or Refractory Hematologic Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Trichostatin A

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsA Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Recruiting

PHASE1

PHASE2

Sponsor:

Krystal Biotech, Inc.

Location:

Indianapolis IN, Nasville TN, Cleveland OH, Pittsburgh PAshow 4 more

Code:

NCT06228326

Conditions

Lung Cancer, Non-small Cell

Lung Cancer Metastatic

Solid Tumor, Adult

Advanced Cancer

Lung Cancer (NSCLC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

KB707

Pembrolizumab (KEYTRUDA®)

Chemotherapy

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGAnticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting

PHASE3

Sponsor:

Icahn School of Medicine at Mount Sinai

Location:

Indianapolis IN, Fort Wayne IN, Columbus OH, Ann Arbor MIshow 45 more

Code:

NCT04045665

Conditions

Atrial Fibrillation

Stroke

Bleeding

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Antiplatelet-only strategy

Oral Anticoagulant plus background antiplatelet therapy

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Indianapolis IN, Cincinnati OH, Fort Wayne IN, Dayton OHshow 172 more

Code:

NCT05026866

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Donanemab

Placebo

Satisfaction With eMotion in a Diverse Group of WomenSatisfaction With eMotion in a Diverse Group of Women

Recruiting

Sponsor:

Indiana University

Location:

Indianapolis IN

Code:

NCT06404866

Conditions

Cardiac Events

Emotions

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

eMotion

An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSAn Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

Recruiting

Sponsor:

XenoPort, Inc.

Location:

Indianapolis IN, Toledo OH, Saint Louis MO, Nashville TNshow 8 more

Code:

NCT02560766

Conditions

RLS

Eligibility Criteria

Sex: All

Age: 13 - 17

Healthy Volunteers: Not accepted

Interventions

HORIZANT 300 mg

HORIZANT 600 mg

Placebo

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Recruiting

PHASE2

Sponsor:

Genentech, Inc.

Location:

Indianapolis IN, Cincinnati OH, Chicago IL, Lexington KYshow 22 more

Code:

NCT05968326

Conditions

Adenocarcinoma, Pancreatic Ductal

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Autogene cevumeran

Atezolizumab

mFOLFIRINOX

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Indianapolis IN, Avon IN, Carmel IN, Mooresville INshow 706 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Recruiting

PHASE1

PHASE2

Sponsor:

RayzeBio, Inc.

Location:

Indianapolis IN, Saint Louis MO, Detroit MI, Cleveland OHshow 18 more

Code:

NCT06590857

Conditions

Metastatic Breast Cancer

HER2-negative Breast Cancer

ER+ Breast Cancer

Advanced Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RYZ101

Popular cities in Indiana

Indianapolis South Bend Fort Wayne Evansville